Nyxoah to Present at Oppenheimer Healthcare Conference Amid U.S. Market Expansion

Event summary

  • Nyxoah CEO Olivier Taelman to present at Oppenheimer Healthcare Conference on March 16, 2026.
  • Company will hold 1x1 meetings with institutional investors during the event.
  • Nyxoah's Genio system received FDA approval in August 2025 for moderate to severe OSA patients.
  • Company expanded European CE mark approval to include Complete Concentric Collapse patients in 2025.

The big picture

Nyxoah's participation in the Oppenheimer conference comes at a critical juncture as it seeks to capitalize on its recent FDA approval and expand its presence in the U.S. sleep apnea treatment market. The company's Genio system represents an innovative approach to OSA treatment, competing with established players in a market projected to reach $8.5 billion by 2028. Nyxoah's ability to articulate its growth strategy and differentiation will be key to attracting institutional investors.

What we're watching

U.S. Market Penetration
How Nyxoah will leverage its recent FDA approval to gain market share in the competitive U.S. sleep apnea treatment market.
Investor Sentiment
Whether the Oppenheimer conference will generate positive momentum for Nyxoah's stock following its FDA approval.
Therapeutic Expansion
The pace at which Nyxoah can expand its Genio system's indications beyond current FDA-approved parameters.